Revelation Biosciences, Inc. (REVB)
3.535
-0.26
(-6.73%)
USD |
NASDAQ |
Oct 26, 16:00
3.50
-0.04
(-0.99%)
After-Hours: 20:00
Revelation Biosciences Enterprise Value : -8.769M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | -8.769M |
| October 23, 2026 | -8.627M |
| October 22, 2026 | -8.688M |
| October 21, 2026 | -8.733M |
| October 20, 2026 | -8.649M |
| October 19, 2026 | -8.909M |
| October 16, 2026 | -8.849M |
| October 15, 2026 | -7.764M |
| October 14, 2026 | -7.930M |
| October 13, 2026 | -7.889M |
| October 12, 2026 | -7.715M |
| October 09, 2026 | -7.773M |
| October 08, 2026 | -7.718M |
| October 07, 2026 | -7.507M |
| October 06, 2026 | -7.803M |
| October 05, 2026 | -7.706M |
| October 02, 2026 | -7.759M |
| October 01, 2026 | -7.612M |
| September 30, 2026 | -7.55M |
| September 29, 2026 | -7.562M |
| September 28, 2026 | -7.385M |
| September 25, 2026 | -7.342M |
| September 24, 2026 | -7.342M |
| September 23, 2026 | -7.091M |
| September 22, 2026 | -6.913M |
| Date | Value |
|---|---|
| September 21, 2026 | -6.927M |
| September 18, 2026 | -7.107M |
| September 17, 2026 | -7.030M |
| September 16, 2026 | -7.147M |
| September 15, 2026 | -7.185M |
| September 14, 2026 | -7.010M |
| September 11, 2026 | -6.864M |
| September 10, 2026 | -6.837M |
| September 09, 2026 | -6.796M |
| September 08, 2026 | -6.796M |
| September 04, 2026 | -6.796M |
| September 03, 2026 | -6.796M |
| September 02, 2026 | -6.835M |
| September 01, 2026 | -6.887M |
| August 31, 2026 | -6.835M |
| August 28, 2026 | -6.639M |
| August 27, 2026 | -6.718M |
| August 26, 2026 | -7.011M |
| August 25, 2026 | -6.835M |
| August 24, 2026 | -6.444M |
| August 21, 2026 | -6.483M |
| August 20, 2026 | -6.561M |
| August 19, 2026 | -6.405M |
| August 18, 2026 | -6.405M |
| August 17, 2026 | -6.249M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Shuttle Pharmaceuticals Holdings, Inc. | 5.156M |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
| Agenus, Inc. | 527.17M |
| Alnylam Pharmaceuticals, Inc. | 30.13B |
| Amgen, Inc. | 283.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.323M |
| Total Expenses (Quarterly) | 3.323M |
| EPS Diluted (Quarterly) | -6.075 |
| Earnings Yield | -2.44K% |
| Normalized Earnings Yield | -2435.45 |